Several Lots of Human Growth Hormone Have Been Recalled
An FDA inspection of compound pharmacy Innoveix Pharmaceuticals indicated these lots may not be sterile.
Innoveix Pharmaceuticals, a compounding pharmacy in Addison, Tex., is voluntarily recalling several lots of compounded drug products. The products are being recalled due to a lack of assurance of sterility. The issues where discovered during a routine inspection by the FDA.
The affected products are injectable sermorelin/ipamorelin 3mg and injectable AOD-9604 3mg. Sermorelin and ipamorelin are human growth hormone secretagogues (GHSs), which are compounds that increase growth hormone release. AOD is a synthetic peptide thought to have potential for weight loss.
To date, Innoveix Pharmaceuticals has not received any reports of adverse events related to this recall.
Sermorelin / Ipamorelin 3mg
- Lot# SIP210; Exp: 12/15/2021
- Lot# SIP215; Exp: 01/14/2022
- Lot# SIP220; Exp: 01/23/2022
AOD-9604 3mg
- Lot# AOD205; Exp: 11/09/2021
- Lot# AOD210; Exp: 11/18/2021
- Lot# AOD 215; Exp: 12/15/2021
- Lot# AOD202; Exp: 11/09/2021
Navitus to Offer Unbranded Stelara Biosimilar, Remove Stelara from Formulary
March 13th 2025Lumicera Health Services, Navitus’ specialty pharmacy, has made a deal with Teva to offer an unbranded biosimilar that they estimate will save $112,000 and $336,000 per patient per year. Navitus will remove Stelara from formulary on July 1, 2025.
Read More
FDA Approves Neffy 1 mg Nasal Spray for Pediatric Patients
March 6th 2025Neffy 1 mg is now approved by the FDA to treat pediatric patients who weigh 33 to 65 lbs. Neffy was first FDA-approved as a 2 mg dose in August 2024 for the emergency treatment of anaphylaxis in children and adults weighing at least 66 lbs.
Read More
